SAR247799

SAR247799 is an oral, selective, G-protein-biased sphingosine-1-phosphate receptor-1 (S1P1) agonist. It is designed to activate S1P1 on endothelial cells without causing receptor desensitization or lymphopenia—a side effect seen with other S1P modulators used in autoimmune diseases. By preferentially activating G protein signaling over β-arrestin pathways, SAR247799 preserves and restores endothelial function and barrier integrity. This mechanism makes it a potential therapeutic candidate for diseases associated with endothelial dysfunction such as coronary artery disease, peripheral artery disease, diabetic complications (retinopathy, nephropathy), heart failure (including left ventricular hypertrophy and diastolic dysfunction), microvascular angina, myocardial infarction, stroke, vascular dementia, sickle cell disease, chronic rheumatic disorders (e.g., Raynaud's phenomenon), acute lung injury/acute kidney injury and vascular leak syndromes[1][3][4][5][7]. The drug has demonstrated cardio-protective effects in preclinical models by improving diastolic function and reducing cardiac hypertrophy without affecting immune cell counts[7]. It is being developed by Sanofi.

Other names

S1P1 agonist 3S-1P1 agonist 3S 1P1 agonist 3